Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab in Chinese Patients With Moderate-to-Severe Plaque Psoriasis
NCT03364309Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2018
- Primary completion
- Jun 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ixekizumab in plaque psoriasis, sponsored by Eli Lilly and Company. Started Apr 2018; status: completed.
02
Drugs
ixekizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03364309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03364309.